Sam’s practice focuses on life sciences IP litigation, including Hatch-Waxman ANDA actions, BPCIA biosimilar disputes, and inter partes review proceedings before the U.S. Patent and Trademark Office. Sam combines over a decade of trial and litigation experience and has advised major pharmaceutical, biotechnology, and medical device companies on IP disputes spanning oncology, metabolic, CNS, and ophthalmology therapeutic areas. He has represented both brand-side innovators—including Boehringer Ingelheim, Moderna, Eli Lilly, Bristol-Myers Squibb, Pfizer, and Vertex—and biosimilar and generic challengers, including Samsung Bioepis, Celltrion, and Teva.
Sam Kwon
Partner
212.518.2892
sam.kwon@gishllp.com
Sam is a seasoned IP litigator with extensive experience counseling pharmaceutical and biotechnology clients in high-stakes IP disputes. At Kirkland & Ellis, Sam managed an extensive portfolio of life sciences matters, developing deep expertise across composition-of-matter, formulation, polymorph, method-of-use, and manufacturing process patents for drugs spanning major therapeutic areas.
Sam brings a rare dual perspective to his practice, having represented both brand-side innovators and biosimilar/generic challengers. This experience gives him unique insight into the strategies employed on both sides of pharmaceutical patent disputes, enabling him to craft more effective and creative litigation strategies for his clients.